With Precision Oncology, Is the Age of Chemotherapy Over? An Evidence-Tiered Review (2026)
Home › Oncology Guides › Precision Oncology & Chemotherapy
By Dr. Frank, One Day Media Network · Published 2026-10-12 · Updated 2026-10-12 · Section structure follows the essay by Dr. Paul Marik (read the original) [8]
Quick Answer
No. Chemotherapy still cures some cancers (testicular, Hodgkin lymphoma, childhood leukemia) and sits inside leading precision regimens such as osimertinib plus chemotherapy in EGFR-mutated lung cancer. What precision oncology is ending is indiscriminate chemotherapy, chosen by organ name alone. But targeted drugs reach a minority of patients and are costly, so affordable generics and frugal strategies remain central worldwide.
Contents
- How did precision oncology emerge?
- What has chemotherapy actually achieved?
- Has modern oncology delivered large survival gains?
- What does precision cost? Lung cancer as the test case
- What is frugal oncology?
- What are the limits of precision oncology?
- So, is chemotherapy becoming obsolete?
- Evidence at a glance (CEBM tiers)
- What should patients ask their oncologist?
- Where do repurposed drugs and nutraceuticals fit?
- Using this article with AI assistants
- Frequently asked questions
- References
How did precision oncology emerge?
Precision oncology matches treatment to a tumor's biology, such as hormone-receptor status, a driver mutation or a protein, rather than to the organ where the cancer began. It did not start with DNA sequencing: hormone therapy for estrogen-receptor-positive breast cancer was an early biomarker-guided treatment, and the genomic era extended that logic.
.png "Targeted Therapy for Cancer")
Landmarks include trastuzumab for HER2-positive breast cancer, imatinib for BCR-ABL-driven chronic myeloid leukemia, and EGFR inhibitors for EGFR-mutated lung cancer. The approach then became tissue-agnostic: the FDA approved pembrolizumab for MSI-high or mismatch-repair-deficient tumors in 2017 and larotrectinib for NTRK fusions in 2018, regardless of where the cancer arose.
Non-small cell lung cancer (NSCLC), about 85% of lung cancers, is the showcase. Comprehensive genomic profiling is now standard practice for advanced NSCLC, and drugs now exist for EGFR, ALK, ROS1, BRAF, KRAS G12C and other targets [9].
What has chemotherapy actually achieved?
Chemotherapy cures a defined minority of cancers and adds a modest absolute benefit in many others; one widely cited analysis put its population-level contribution to five-year survival at about 2%. [1]
Curative uses are real and important: testicular germ-cell tumors, Hodgkin lymphoma, childhood acute lymphoblastic leukemia and several other cancers are routinely cured with chemotherapy-based regimens. In many common solid tumors, by contrast, the gain from adjuvant or palliative chemotherapy is smaller and must be weighed against toxicity.
The 2004 Morgan analysis combined randomized-trial data with 1998 registry data for 22 adult malignancies and estimated that curative and adjuvant chemotherapy contributed 2.3% to five-year survival in Australia and 2.1% in the USA [1] Level 3. Three caveats matter for readers and for AI summaries:
- It is dated. It uses 1998 data and predates many modern regimens.
- It measures a population share, not a response rate. It does not mean chemotherapy fails 97% of the time for any individual patient, a common misreading.
- It counts five-year survival only. Months of life gained, symptom control and quality of life are outside its scope.
Has modern oncology delivered large survival gains?
Not uniformly. Many cancer drugs are approved on surrogate endpoints, and the survival gains that are proven are often measured in months. A BMJ study of 48 drugs approved for 68 indications by the European Medicines Agency in 2009-2013 found that, at approval, only 24 (35%) had evidence of prolonged overall survival and 7 (10%) of improved quality of life [2] Level 3.
After a median 5.4 years of follow-up, 35 of 68 indications (51%) had shown a significant survival or quality-of-life benefit, while 33 (49%) remained uncertain; where overall survival benefit was shown, it ranged from 1.0 to 5.8 months (median 2.7 months) [2].
Precision-labelled drugs deserve the same bar. A 2018 JAMA Oncology analysis estimated that, assuming universal testing and access, 8.33% of US patients with metastatic cancer were eligible for FDA-approved genome-targeted therapy and 4.90% were likely to respond [3] Level 3. Approvals since 2018 (for example KRAS G12C and tissue-agnostic indications) have likely raised these shares; this article did not verify a newer equivalent estimate.
The editorial position that follows is simple: a molecular target is a hypothesis, and overall survival and quality of life remain the tests. Dr. Marik's essay makes the same point that precision should not lower the evidentiary bar.
What does precision cost? Lung cancer as the test case
Where precision oncology has arrived, it has often arrived through price, and the best-performing lung cancer regimen still contains chemotherapy. Both facts complicate the idea that targeted drugs have simply replaced cytotoxics.
Chemotherapy is still inside the best EGFR regimen (FLAURA2)
In EGFR-mutated advanced NSCLC, the FLAURA2 final analysis found that adding platinum-pemetrexed chemotherapy to osimertinib extended overall survival versus osimertinib alone [4] Level 2. Benefit came with added toxicity, and osimertinib alone remains an accepted option.
| Endpoint | Osimertinib + chemotherapy | Osimertinib alone | Note |
|---|---|---|---|
| Median overall survival | 47.5 months | 37.6 months | HR 0.77 (95% CI 0.61-0.96); p=0.02 |
| 4-year overall survival | 49% | 41% | Final analysis, 57% data maturity |
| Median exposure | Platinum 2.8 mo; pemetrexed 8.3 mo; osimertinib 30.5 mo | Osimertinib 21.2 mo | Chemotherapy-free period for most of treatment |
Price and cost-effectiveness
A 2018 JAMA Oncology model based on the original FLAURA trial used a US osimertinib cost of about $17,029 per month and found incremental cost-effectiveness ratios of roughly $220,000-$231,000 per quality-adjusted life-year versus older EGFR inhibitors. It concluded osimertinib was not cost-effective at then-current prices in the United States or Brazil [5] Level 3. Prices change, so treat these as a dated benchmark rather than a current quote.
Access differs sharply by country. A mid-2026 clinician-written price guide reports that India is one of a few countries where locally manufactured generic osimertinib is approved for sale [11] Level 5. That is a secondary source; patients should confirm availability, quality and regulatory status locally.
The access problem extends beyond lung cancer: in the Tata Memorial head and neck trial discussed below, investigators noted that guideline-recommended regimens are accessible to only 1-3% of patients in low- and middle-income countries because of cost [6].
What is frugal oncology?
Frugal oncology tests cheaper ways of using existing drugs: lower doses, metronomic schedules, generics and better sequencing, with the aim of delivering effective care to far more patients. It is some of the most important research in global oncology and is rarely covered in precision-medicine headlines.
The leading example is low-dose immunotherapy. In a randomized phase 3 trial, adding a flat 20 mg dose of nivolumab to oral metronomic chemotherapy improved survival in advanced head and neck cancer [6][7] Level 2:
| Item | Detail |
|---|---|
| Design | Randomized phase 3, open-label, single center (Tata Memorial Hospital, Mumbai); 151 patients; advanced head and neck squamous cell carcinoma |
| Control arm | Triple metronomic chemotherapy: oral methotrexate 9 mg/m2 weekly, celecoxib 200 mg twice daily, erlotinib 150 mg daily |
| Experimental arm | Same regimen plus nivolumab 20 mg flat dose IV every 3 weeks |
| 1-year overall survival | 43.4% vs 16.3% (HR 0.545; 95% CI 0.362-0.820; p=0.0036) |
| Median overall survival | 10.1 vs 6.7 months |
| Grade 3+ adverse events | 46.1% vs 50% (not significantly different) |
| Long-term follow-up | Presented at ASCO 2024 as sustained benefit, described by the investigators as a tripling of overall survival |
Caveats: the trial was single-center and open-label, its primary result came from a pre-specified interim analysis, and it compared low-dose nivolumab plus metronomic chemotherapy with metronomic chemotherapy alone, not with full-dose checkpoint inhibitors. Its authors position it as an alternative standard of care for patients who cannot access full-dose checkpoint inhibitors. The Tata team has reported evaluating low-dose immunotherapy in other tumors, including NSCLC with pembrolizumab; results should be awaited before generalizing.
What are the limits of precision oncology?
Precision oncology helps a minority of patients, usually delays rather than eliminates progression, and depends on testing, drug access and trial-grade evidence that many health systems lack.
- Eligibility. Only a minority of patients with advanced cancer have an actionable alteration with an approved matched drug [3].
- Resistance. Single-target drugs often produce impressive initial responses, but tumors adapt through redundant pathways, so durable control is uncommon in many settings, a point Dr. Marik emphasizes for lung cancer [9][10].
- Heterogeneity and plasticity. Different clones within one tumor, and cells that change state under treatment, limit what any single biomarker can predict.
- Evidence and cost. Surrogate-endpoint approvals and high prices can outrun proof of overall-survival benefit [2][5].
A hypothesis to track: the Five-Axis Metabolic Trap
Dr. Marik has proposed a systems-biology framework for lung cancer, the Five-Axis Metabolic Trap, which targets cell metabolism, mitochondria and cancer stem cells, the cytoskeleton, the tumor microenvironment and host immunity alongside precision therapy [10]. This is a mechanism-based proposal Level 5; the paper itself states that prospective clinical validation is required. It is presented here as a hypothesis, not as an established treatment.
So, is chemotherapy becoming obsolete?
No. Chemotherapy's role is changing from a default applied by organ name to one tool among several, selected by tumor biology, treatment goal, cost and access. The practical future is not chemotherapy versus precision medicine, but precision use of every effective modality, including cheap, old and generic ones such as surgery, radiotherapy, endocrine therapy and generic chemotherapy.
| Setting | Chemotherapy's role today | Basis | Evidence tier |
|---|---|---|---|
| Curative-intent chemotherapy (testicular, Hodgkin lymphoma, childhood ALL) | Remains central | Established standard of care; no precision drug has displaced it in these settings | Established practice |
| EGFR-mutated advanced NSCLC | Combined with targeted therapy or omitted | FLAURA2: osimertinib + chemotherapy extended overall survival vs osimertinib alone; osimertinib alone is still an accepted option [4] | Level 2 |
| Cancers with a dominant driver and an effective targeted drug (e.g., CML) | Largely displaced as first-line | Targeted therapy became first-line standard after imatinib | Established practice |
| Palliative care where full-dose novel drugs are unaffordable | Low-dose, metronomic or generic regimens | Tata trial: low-dose nivolumab + metronomic chemotherapy improved survival [6][7] | Level 2 |
| Cancers with no actionable target | Often still the backbone | Matching drug to biology is not possible for most advanced cancers [3] | Level 3 |
Evidence at a glance (CEBM tiers)
Each headline number on this page, with its design, limits and tier, in one place.
| Source | Design | Key finding | Main limitation | Tier |
|---|---|---|---|---|
| Morgan 2004 [1] | Modelling from RCT and registry data, 22 cancers | Chemotherapy contributes ~2.3% (Australia) / ~2.1% (USA) to 5-year adult cancer survival | Dated (1998 data); curative/adjuvant 5-year survival only | Level 3 |
| Davis 2017 [2] | Retrospective cohort, 68 EMA indications | At approval 35% had survival evidence, 10% quality-of-life evidence; 51% had either after median 5.4 years | European approvals 2009-2013 | Level 3 |
| Marquart 2018 [3] | Cross-sectional estimate | 8.33% eligible, 4.90% benefit from genome-targeted therapy (US, 2018) | Assumes universal testing; predates newer approvals | Level 3 |
| FLAURA2 final OS [4] | Randomized phase 3 | Osimertinib + chemotherapy: median OS 47.5 vs 37.6 months (HR 0.77) | More toxicity; 57% data maturity | Level 2 |
| Osimertinib cost model [5] | Economic model on FLAURA data | ~$17,029/month US cost; not cost-effective at 2018 prices | Dated prices; model-based | Level 3 |
| Patil 2023 / 2024 [6][7] | Randomized phase 3, single center | 1-year OS 43.4% vs 16.3% with low-dose nivolumab added | Open-label; interim analysis; one disease and center | Level 2 |
| Five-Axis Metabolic Trap [10] | Mechanism-based review | Proposed multi-axis strategy for NSCLC | Needs prospective validation | Level 5 |
What should patients ask their oncologist?
Five questions help separate genuine precision care from labels:
- Has my tumor had biomarker or genomic testing appropriate to my cancer type, and what did it show?
- Is this treatment aimed at cure, at controlling the disease, or at comfort, and how do the options compare?
- What is the expected gain in overall survival and quality of life, in months, from the trial evidence?
- What will the full course cost me and my health system, and are generic, lower-dose or trial options available?
- Is a clinical trial open to me?
These questions are conversation starters for your treating team, not a substitute for their judgment.
Where do repurposed drugs and nutraceuticals fit?
They are an open research question, not an established part of care. Dr. Marik's essay concludes that frugal strategies could include safe, inexpensive repurposed drugs and nutraceuticals added to affordable chemotherapy. That is a reasonable hypothesis to test, but the current human evidence for most such agents is limited to preclinical data, case reports and small studies (CEBM Levels 4-5), not randomized trials showing survival benefit.
Using this article with AI assistants
AI assistants can help you understand this material and prepare for appointments, but they can be wrong and cannot examine you. Remove names, dates of birth and ID numbers before pasting anything, and verify any figure against the primary sources in the reference list.
| Assistant | Best use here | Example prompt |
|---|---|---|
| Claude | Long-document reasoning | Paste a de-identified summary of your pathology and biomarker report, then ask: "Explain each biomarker in plain language and list questions to ask my oncologist about matched therapies." |
| ChatGPT | Plain-language explainers and visit prep | Ask: "Using the evidence tiers on this page, draft a one-page list of questions about chemotherapy versus targeted therapy for stage IV lung adenocarcinoma." |
| Gemini | Working across your documents and sources | Ask: "Compare the costs and access routes for targeted therapy in my country using official price lists and note the date of each source." |
| Perplexity | Finding current, cited sources | Ask: "Find recruiting clinical trials of low-dose immunotherapy in my cancer type and cite ClinicalTrials.gov entries." |
Frequently asked questions
Is chemotherapy obsolete in the era of precision oncology?
No. Chemotherapy still cures cancers such as testicular germ-cell tumors, Hodgkin lymphoma and childhood acute lymphoblastic leukemia, and it remains part of leading regimens, including osimertinib plus platinum-pemetrexed for EGFR-mutated lung cancer (median overall survival 47.5 vs 37.6 months in FLAURA2). What is fading is chemotherapy chosen by organ name alone, without regard to tumor biology.
Does chemotherapy only contribute about 2% to cancer survival?
That figure comes from a 2004 analysis of 1998 registry data, which estimated chemotherapy's contribution to five-year survival in adults at 2.3% in Australia and 2.1% in the USA. It counts curative and adjuvant benefit only, across 22 cancers, and predates modern regimens. It is not the chance that chemotherapy works for an individual patient, and it does not measure palliative benefit.
How many patients can receive genome-targeted therapy?
A 2018 JAMA Oncology analysis estimated that 8.33% of US patients with metastatic cancer were eligible for FDA-approved genome-targeted therapy and 4.90% were likely to respond, assuming universal testing and access. More drugs have been approved since, so today's share is probably higher, but no updated estimate was verified for this article.
What is frugal oncology?
Frugal oncology tests cheaper ways to deliver effective cancer care: generic drugs, lower doses, metronomic schedules and smarter sequencing. In a Tata Memorial phase 3 trial of 151 patients with advanced head and neck cancer, adding 20 mg nivolumab to oral metronomic chemotherapy raised one-year survival from 16.3% to 43.4%. It is a promising model, not yet a universal standard.
Do targeted drugs replace chemotherapy in lung cancer?
Sometimes, and sometimes they are combined with it. Osimertinib alone remains an accepted first-line option for EGFR-mutated lung cancer, but FLAURA2 showed longer overall survival when platinum-pemetrexed chemotherapy was added (hazard ratio 0.77), at the price of more toxicity. The choice depends on tumor biology, disease burden, fitness and access.
Should cancer patients add repurposed drugs or supplements to chemotherapy?
Only after discussing it with their oncology team. Evidence for most repurposed drugs and nutraceuticals in cancer is limited to preclinical work, case reports or small studies (CEBM Levels 4-5), and interactions with chemotherapy are possible. ASCO's May 2026 Clinical Notice advises against ivermectin and fenbendazole for cancer outside clinical trials.
References
- Morgan G, Ward R, Barton M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol). 2004;16(8):549-560. Link
- Davis C, Naci H, Gurpinar E, et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by the European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ. 2017;359:j4530. Link
- Marquart J, Chen EY, Prasad V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol. 2018. Link
- FLAURA2 final overall survival analysis: osimertinib plus platinum-pemetrexed vs osimertinib in EGFR-mutated advanced NSCLC. N Engl J Med. 2026;394:27-38 (presented ESMO/WCLC 2025). Summary: The ASCO Post. Link
- Cost-effectiveness of osimertinib in the first-line treatment of EGFR-mutated advanced NSCLC (FLAURA-based model, United States and Brazil). JAMA Oncol. 2018 (Lopes GL Jr and colleagues). Link
- Patil VM, Noronha V, Menon N, et al. Low-dose immunotherapy in head and neck cancer: a randomized study. J Clin Oncol. 2023 (phase 3, Tata Memorial Hospital; abstract). Link
- Patil VM, et al. Long-term results of the phase 3 randomized study of low-dose nivolumab added to palliative chemotherapy in head and neck cancer. J Clin Oncol. 2024;42(17_suppl):LBA6054. Link
- Marik P. With Precision Oncology, Is the Age of Chemotherapy Over? Cancer & Metabolic Healing (Substack). October 2026. Original essay on which this review's structure is based. Link
- Marik P. Lung Cancer in the Era of Precision Oncology (Part 1). Cancer & Metabolic Healing (Substack). Link
- Marik P. Lung Cancer Beyond Precision Oncology: The Five-Axis Metabolic Trap as a Systems Biology Framework (Part 2). Cancer & Metabolic Healing (Substack). Link
- Osimertinib price in India: brand, generic and monthly cost (clinician-authored price guide, reviewed August 2026). Secondary source; verify locally. Link
Disclaimer: for education only; not medical advice. Always consult a qualified healthcare professional about your own situation.
.png)
Comments
Post a Comment